Seattle Genetics

Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion
Seattle Genetics? Not anymore. The biotech has shortened its name to Seagen to illustrate global expansion
Endpoints
Seattle Genetics
Seagen
name change
expansion
Flag link:
Why Seattle Genetics Stock Jumped 24% in September
Why Seattle Genetics Stock Jumped 24% in September
Motley Fool
Seattle Genetics
Merck
oncology
Tukysa
Flag link:
Seattle Genetics stays step ahead of rivals with bladder cancer data
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Seattle Genetics
Astellas
Padcev
bladder cancer
clinical trials
ESMO
Flag link:
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
Flag link:
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
EP Vantage
cervical cancer
tisotumab vedotin
Genmab
Seattle Genetics
clinical trials
Flag link:
Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water
Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water
Fierce Pharma
Seattle Genetics
Padcev
bladder cancer
Flag link:
FDA approves first new drug under Project Orbis
FDA approves first new drug under Project Orbis
RAPS.org
FDA
Seattle Genetics
Tukysa
advanced HER2-positive breast cancer
breast cancer
Project Orbis
Flag link:
How a Seattle Genetics cancer drug could help lupus patients with kidney damage
How a Seattle Genetics cancer drug could help lupus patients with kidney damage
Fierce Biotech
Seattle Genetics
lupus
kidney damage
PX-478
Flag link:
Seattle Genetics Issue Update on Padcev Label Expansion Study
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Flag link:
Seattle could waltz in where Astra failed
Seattle could waltz in where Astra failed
EP Vantage
AstraZeneca
Imfinizi
bladder cancer
Seattle Genetics
clinical trials
Padcev
Flag link:
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Fierce Pharma
Astellas
Seattle Genetics
Padcev
advanced bladder cancer
bladder cancer
Flag link:
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Seattle Genetics' Experimental Breast Cancer Drug Receives Priority Review From the FDA
Motley Fool
Seattle Genetics
tucatinib
FDA
priority review
breast cancer
HER-2 postive breast cancer
Flag link:
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Reuters
Seattle Genetics
Astellas
bladder cancer
Padcev
Flag link:
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Flag link:
Seattle Genetics Reports Q4 Earnings Results
Seattle Genetics Reports Q4 Earnings Results
Motley Fool
Seattle Genetics
earnings
Flag link:
Are Biotech Stocks Due for a Correction in 2020?
Are Biotech Stocks Due for a Correction in 2020?
Motley Fool
biotech stocks
Axsome Therapeutics
Seattle Genetics
Vertex Pharmaceuticals
Flag link:
3 Blockbuster Cancer Drug Launches to Watch in 2020
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Flag link:
Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev
Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev
Fierce Pharma
Seattle Genetics
Astellas
FDA
Padcev
metastatic bladder cancer
Flag link:
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data
Fierce Biotech
Seattle Genetics
breast cancer
tucatinib
HER2+ breast cancer
SABCS
Flag link:
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
BioSpace
Seattle Genetics
Daiichi Sankyo
antibody-drug conjugate
Flag link:

Pages